Patents by Inventor Stacey Shepard

Stacey Shepard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1
    Publication number: 20260098044
    Abstract: The present application provides tricyclic heteroaryl compounds that modulate the activity of the JAK1 and/or TYK2, which are useful in the treatment of various disorders and diseases, including skin, respiratory, ophthalmic, and rectal diseases and disorders, cancer, and neuroinflammation.
    Type: Application
    Filed: October 2, 2025
    Publication date: April 9, 2026
    Inventors: Stacey Shepard, Onur Atasoylu, Song Mei, Jun Pan
  • Tertiary alcohols as PI3K-? inhibitors
    Patent number: 12516065
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: February 1, 2024
    Date of Patent: January 6, 2026
    Assignee: Incyte Corporation
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS
    Publication number: 20250388553
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: August 22, 2025
    Publication date: December 25, 2025
    Inventors: Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue, Andrew W. Buesking
  • FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS
    Publication number: 20250333420
    Abstract: The present application is concerned with bicyclic pyrimidinones as inhibitors of WRN, as well as pharmaceutical compositions and methods of use related thereto. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 13, 2024
    Publication date: October 30, 2025
    Applicant: INCYTE CORPORATION
    Inventors: Stacey SHEPARD, Yanran AI, Joe BARBOSA, Marc DELLER, Ananda GHOSH, Joe Glenn, JR., Leslie McQUIRTER, Lixin SHAO, Xiaozhao WANG, Eddy YUE, Guofeng ZHANG
  • AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20250313550
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: June 17, 2025
    Publication date: October 9, 2025
    Inventors: Stacey Shepard, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao
  • Aminopyrazine derivatives as PI3K-? inhibitors
    Patent number: 12421197
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: September 23, 2025
    Assignee: Incyte Corporation
    Inventors: Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue, Andrew W. Buesking
  • IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS
    Publication number: 20250270218
    Abstract: Disclosed are compounds of Formula (I) and Formula (II), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: November 20, 2024
    Publication date: August 28, 2025
    Applicant: Incyte Corporation
    Inventors: Stacey SHEPARD, Yanran AI, Joe BARBOSA, Marc DELLER, Nikoo FALAHATPISHEH, Ananda GHOSH, Joe Glenn, JR., Leslie McQUIRTER, Yehao QIU, Cooper TAYLOR, Xiaozhao WANG, Eddy YUE, Guofeng ZHANG
  • IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS
    Publication number: 20250270217
    Abstract: Disclosed are compounds of Formula (I) and Formula (II), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: November 20, 2024
    Publication date: August 28, 2025
    Applicant: Incyte Corporation
    Inventors: Yanran AI, Joe BARBOSA, Huan CHEN, Marc DELLER, Balu D. DHERANGE, Nikoo FALAHATPISHEH, Ananda GHOSH, Joe Glenn, JR., Yong LI, Leslie McQUIRTER, Yehao QIU, Stacey SHEPARD, Cooper TAYLOR, Xiaozhao WANG, Eddy Yue, Guofeng ZHANG, Le ZHAO, Zhitong ZHENG
  • Aminopyrazine diol compounds as PI3K-y inhibitors
    Patent number: 12365668
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: February 1, 2024
    Date of Patent: July 22, 2025
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao
  • TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN
    Publication number: 20250215006
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: October 14, 2024
    Publication date: July 3, 2025
    Applicant: Incyte Corporation
    Inventors: Yanran Ai, Joe Barbosa, Ananda Ghosh, Marc D. Deller, Joe Glenn, JR., Leslie McQuirter, Yehao Qiu, Lixin Shao, Stacey Shepard, Cooper Taylor, Xiaozhao Wang, Eddy Yue, Guofeng Zhang
  • SPIROCYCLIC LACTAM INHIBITORS
    Publication number: 20250101020
    Abstract: The present application provides bicyclic spriolactam compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: September 20, 2024
    Publication date: March 27, 2025
    Inventors: Stacey Shepard, Lixin Shao, Xiaozhao Wang, Eddy W. Yue
  • AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20240400541
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: February 1, 2024
    Publication date: December 5, 2024
    Inventors: Stacey Shepard, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao
  • TERTIARY ALCOHOLS AS PI3K-y INHIBITORS
    Publication number: 20240228498
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: February 1, 2024
    Publication date: July 11, 2024
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors
    Patent number: 12030885
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
  • Heterocyclic derivatives as PI3K inhibitors
    Patent number: 12006320
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: June 11, 2024
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart
  • Spirocyclic lactams as JAK2 V617F inhibitors
    Patent number: 11958861
    Abstract: The present application provides spirocyclic lactam compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: April 16, 2024
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Charles Cole, Nikoo Falahatpisheh, Kai Liu, Lixin Shao, Darius Vrubliauskas, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Pyridine and pyridimine compounds as PI3K-gamma inhibitors
    Patent number: 11952367
    Abstract: The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3K?) and are useful in the treatment of diseases related to the activity of PI3K? including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: April 9, 2024
    Assignee: Incyte Corporation
    Inventors: Richard B. Sparks, Stacey Shepard, Andrew P. Combs, Andrew W. Buesking, Lixin Shao, Haisheng Wang, Nikoo Falahatpisheh
  • Tertiary alcohols as PI3K-? inhibitors
    Patent number: 11926630
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: March 12, 2024
    Assignee: Incyte Corporation
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • Aminopyrazine diol compounds as PI3K-? inhibitors
    Patent number: 11926616
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: March 12, 2024
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao
  • Heterocyclic compounds as PI3K-? inhibitors
    Patent number: 11773102
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: October 3, 2023
    Assignee: Incyte Corporation
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri